PMV can sell up to $113,792,846.40 of stock through Jefferies, which the filing says is paid 3.0% of gross proceeds. The stock last sold at $1.59 per share on November 19, 2024, far below the $6.97 weighted average on the earlier program.
Latest PMV Pharmaceuticals news
We have not published a story on PMV Pharmaceuticals yet. When there is news, it will appear here.
Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $12.5 million, plus short-term investments of $67.0 million, $79.4 million in all.
Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.
Questions about PMV Pharmaceuticals
Has PMV Pharmaceuticals raised money recently?
Our latest story on this, dated Nov 20, 2024: "PMV Pharmaceuticals files $200,000,000 shelf with $113,792,846.40 ATM supplement". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of PMV Pharmaceuticals?
PMV Pharmaceuticals, Inc. trades under the ticker PMVP on NASDAQ.
Where is PMV Pharmaceuticals listed?
PMV Pharmaceuticals, Inc. is listed on NASDAQ.
What is the SEC CIK of PMV Pharmaceuticals?
The SEC Central Index Key (CIK) for PMV Pharmaceuticals, Inc. is 1699382. Its filings are on SEC EDGAR.
How many shares does PMV Pharmaceuticals have outstanding?
53,458,058 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14.
Which country or territory is PMV Pharmaceuticals listed under?
Our directory records PMV Pharmaceuticals, Inc. under United States.
What does PMV Pharmaceuticals do?
Our directory classifies PMV Pharmaceuticals, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of PMV Pharmaceuticals?
The ISIN recorded for PMV Pharmaceuticals, Inc. is US69353Y1038.
Does aibio.space cover PMV Pharmaceuticals?
aibio.space lists PMV Pharmaceuticals, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is PMV Pharmaceuticals incorporated?
SEC records list its state or country of incorporation as DE.
Is PMV Pharmaceuticals profitable?
PMV Pharmaceuticals, Inc. reported a net loss of $77.7 million for the fiscal year ended Dec 31, 2025, and used $73.6 million of cash in operations, per its annual report to the SEC.
How much does PMV Pharmaceuticals spend on research and development?
$69.9 million in the fiscal year ended Dec 31, 2025, per its annual report.
How much cash does PMV Pharmaceuticals have?
$79.4 million in cash and short-term investments at Jun 30, 2026, per its 10-Q.
What is the latest PMV Pharmaceuticals (PMVP) stock news?
Our latest story on PMV Pharmaceuticals, dated Nov 20, 2024: "PMV Pharmaceuticals files $200,000,000 shelf with $113,792,846.40 ATM supplement". PMV can sell up to $113,792,846.40 of stock through Jefferies, which the filing says is paid 3.0% of gross proceeds. The stock last sold at $1.59 per share on November 19, 2024, far below the $6.97 weighted average on the earlier program. Source.
What is PMV Pharmaceuticals's market cap?
We do not publish live share prices. In its annual report, PMV Pharmaceuticals, Inc. put the market value of shares held by non-affiliates (public float) at $53.4 million as of Jun 30, 2025.
Investor discussion: PMV Pharmaceuticals
Members talk about PMV Pharmaceuticals (PMVP). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at PMV Pharmaceuticals, newest first. Each line links the filing it comes from.
Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Financings
Set up an at-the-market program to sell shares over time. SEC Form S-3. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:PMVP on TradingView.
SEC filings and registration
SEC name
PMV Pharmaceuticals, Inc.
CIK
1699382
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
PMVP (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company
Business address
400 ALEXANDER PARK DRIVE, PRINCETON, NJ, 08540
Phone
(609) 642-6670
Shares outstanding
53,458,058 as of 2026-08-14 (10-Q filed 2026-08-14)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
PMV Pharmaceuticals, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PMVP, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio